Trial Profile
Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP 0.5%
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Travoprost (Primary) ; Timolol
- Indications Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Glaukos Corporation
- 07 Dec 2023 Primary endpoint has been met. (IOP (mmHg) at Week 12), as per Results published in the Drugs
- 07 Dec 2023 Results published in the Drugs
- 27 Jun 2023 Status changed from active, no longer recruiting to completed.